AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
InMed Pharmaceuticals Inc. Common Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SDV3N2
1.44▲ 0.11 (8.27%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
1.33
Day's Range
1.32 – 1.54
52-Week Range
0.58 – 2.33
Volume
125.9K
Avg Volume
51.9K
Share Statistics
Shares Outstanding
Employees
13
Exchange
XNAS
Listed
2020-11-10
Share count as of September 2, 2026

InMed Pharmaceuticals Inc. Common Shares (INM) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about InMed Pharmaceuticals Inc. Common Shares (INM)
What is InMed Pharmaceuticals Inc. Common Shares's Market Cap?
InMed Pharmaceuticals Inc. Common Shares's Market Cap is $7.9M, based on as-reported figures from SEC (XBRL) filings.
What is InMed Pharmaceuticals Inc. Common Shares's Price / Sales?
InMed Pharmaceuticals Inc. Common Shares's Price / Sales is 1.6×, based on as-reported figures from SEC (XBRL) filings.
What is InMed Pharmaceuticals Inc. Common Shares's Revenue (TTM)?
InMed Pharmaceuticals Inc. Common Shares's Revenue (TTM) is $4.9M, based on as-reported figures from SEC (XBRL) filings.
What is InMed Pharmaceuticals Inc. Common Shares's Net Income (TTM)?
InMed Pharmaceuticals Inc. Common Shares's Net Income (TTM) is -$8.5M, based on as-reported figures from SEC (XBRL) filings.
What is InMed Pharmaceuticals Inc. Common Shares's EBITDA?
InMed Pharmaceuticals Inc. Common Shares's EBITDA is -$8.3M, based on as-reported figures from SEC (XBRL) filings.
What is InMed Pharmaceuticals Inc. Common Shares's Diluted EPS (TTM)?
InMed Pharmaceuticals Inc. Common Shares's Diluted EPS (TTM) is -1.55, based on as-reported figures from SEC (XBRL) filings.
What is InMed Pharmaceuticals Inc. Common Shares's EBITDA Margin?
InMed Pharmaceuticals Inc. Common Shares's EBITDA Margin is -167.9%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · INMAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating Expenses
Research and development
General and administrative
Amortization and depreciation
Foreign exchange loss
Total operating expenses
Other Income (Expense)
Interest and other income
Finance expense————
Loss from continuing operations before taxes
Net loss from continuing operations——
Net Loss
Net loss per share attributable to Common Stockholders – basic (in Dollars per share)
Net loss per share attributable to Common Stockholders – diluted (in Dollars per share)